Bladder cancer highlights from ESMO 2025 скачать в хорошем качестве

Bladder cancer highlights from ESMO 2025

Prof. Thomas Powles joins us in Berlin to share his perspectives on the latest bladder cancer data presented at ESMO 2025. Prof. Powles reviews data from the following studies: KEYNOTE-905: Perioperative enfortumab vedotin plus pembrolizumab in participants with muscle-invasive bladder cancer who are cisplatin-ineligible: The phase 3 study. Vulsteke C, et al. Abstract LBA2, ESMO 2025 ALBAN: A phase 3, randomised, open-label, international study of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) vs BCG alone in BCG-naïve high-risk, non-muscle-invasive bladder cancer. Roupret M, et al. Abstract LBA107, ESMO 2025 IMvigor011: a phase 3 trial of circulating tumour DNA-guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer. Powles T.B, et al. Abstract LBA8, ESMO 2025 How will these data impact clinical practice? Watch to find out! See more updates from ESMO 2025 on our website: https://cor2ed.com/n-connect/programm... Looking for similar GU cancer programmes? Update From ASCO 2025: https://cor2ed.com/n-connect/programm... Interactive patient case video: Shared decision-making for prostate cancer patients: https://cor2ed.com/gu-connect/program... Follow GU CONNECT on: X – https://x.com/guconnectinfo LinkedIn –   / gu-connect   This video was developed by cor2ed.com Published October 2025 Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.